The Ledger · 2 issues

Skincare journalism,
on the record.

The Ledger is where Uwazia takes positions. Long-form essays on actives, regulation, melanin-rich biology, and the brands shaping the industry — read from primary literature, written without hype. No sponsored copy. No affiliate links. No “skincare is complicated.”

For informational purposes only. For medical advice or a diagnosis, consult a professional.

What you’ll find here

Investigative pieces that read primary literature, regulatory filings, and clinical trial registries — then translate the findings into actionable label-reading guidance. Each article addresses melanin-rich phototypes specifically when the science diverges.

02

In development

Drafting next.

  • № 01

    Pigmentation

    The melasma protocol

    Triple combination therapy, the rise of tranexamic acid, and what the evidence says about each route.

  • № 02

    Sunscreen

    Why US sunscreens lag a decade

    Bemotrizinol, bisoctrizole, Tinosorb — the filters Asia and the EU have had for years that Americans still can't buy.

  • № 03

    Label literacy

    Reading an INCI list

    How to spot filler ingredients, fragrance hiding spots, and the 1% line — without a chemistry degree.

  • № 04

    Phototype

    Sunscreen the studies forgot

    Why most SPF research is run on Fitzpatrick I–III skin, and what that means if you're IV–VI.

Subscribe to the Ledger

Each issue, in your inbox.

One email per issue. No marketing copy, no affiliate links, no other lists. We won’t share the address. Unsubscribe in one click.

We send when a new Ledger issue publishes — roughly monthly. Your email isn't used for anything else.